BioCorRx Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
BioCorRx Inc. (BICX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$118.12 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $72.55K.
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$63.89K, a 278.18% decline year-over-year.
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $35.86K, a 73.45% decline year-over-year.
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $135.07K, a 6.08% increase year-over-year.
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $51.33K, a 125.01% increase from fiscal 2024.
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $22.81K.
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$3.39K.
- BioCorRx Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$17.22K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$118.12K 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $72.55K 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $51.33K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $199.66K 10-K · filed 2026-03-31 | |||
| 2025-06-30 | $23.84K 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$63.89K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $22.81K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$65.13K 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$56.86K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $35.86K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$3.39K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $87.79K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $128.69K 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $135.07K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$17.22K 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$22.31K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $25.62K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $127.33K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$506.21K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $153.40K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $111.11K 10-Q · filed 2022-08-15 |